building the bridge between foundation and industry · four pillars therapeutic areas...
TRANSCRIPT
1
To avoid any technical difficulties and to listen in without any problems, please login through WebEx first before calling in.
You may be able to call in through your phone or computer. The number to use to call in is to the right of this screen.
Use this Access Code to join: 667 719 316
And your individual ID number was emailed to you.
If you have any technical issues or concerns, please reach out to Ashley, [email protected].
US TOLLFREE+1-855-749-4750US TOLL+1-415-655-0001
Building the Bridge Between Foundation and Industry
Building the Bridge Between Foundation and
Industry
3
Throughout the webinar, panelists will be taking questions from the audience
To send in questions, please use WebEx’s Q&A feature in the bottom right hand corner
Please feel free to submit questions throughout the presentation
Submit Your Questions
Meet Today’s Panelists:
4
Daniel LevineLevine Media Group
Ann Marie BingoManager, Global Patient Advocacy
Horizon Pharma
Anne BrunsAssociate Executive Director and
Operations ManagerThe Atypical HUS Foundation
Moderator:
Panelists:
5
Ann Marie Bingo Manager, Global Patient Advocacy
Horizon Pharma
About Horizon
• Founded in 2005
– Biopharmaceutical company with strong growth
• Corporate headquarters in Dublin, Ireland
• U.S. operations inLake Forest, Illinois
• 1000+ employees
• Eleven medicines treating rare diseases, arthritis and inflammation
6
Focused Commitment to Our Community
Four Pillars
Therapeutic Areas STEM/Education Innovation Children’s Healthcare
7
Industry & Foundations
• Approaching Industry
– Clear goals & plans
– Clear Ask
– Willingness to have open & honest discussions
• Keys to a good relationship
– Open & honest discussions
– Know when to get involved and when to step out
– Education
8
Why is the relationship important?
• Patient Groups are the voice of the disease community
– They focus on meeting the community’s particular needs
• As an Industry, we need to listen and learn from these communities to be successful
• Clinical Trial development
• Drug Approval
• Continued relationship
9
Our Approach: Participate, Listen, Learn
10
Horizon Team at local walk
TZ the IDF Zebra at Horizon’s Lake Forest Office
Cystinosis Research Network Conference Activity
Providing Resources Based on Our Learnings
11
Resources Created Together with the Community
12
Long-Term Commitment
13
RAREis Launched on Rare Disease Day 2017
14
Awareness initiative unites the faces of the rare disease community
15
Anne Bruns Associate Executive Director and
Operations ManagerThe Atypical HUS Foundation
What is Atypical HUS?aHUS is an extremely rare, life-threatening disease caused by chronic, uncontrolled activation of the complement system. The disease can cause systemic TMA, leading to stroke, heart attack, hypertension, kidney failure, encephalopathy, seizures, pancreatitis, liver necrosis, intestinal ischemia and death.
Our Community
Creating a Relationship
• Understand regulations for industry- ask!
• Set your own standards and stick to them
• Share your projects, your plans and your goals
• Think outside of the box on ways to work together
• Be open to ideas
• Frequent contact and follow up
• Be appreciative
18
Questions and Answers
Thank You Panelists:
19
Daniel LevineLevine Media Group
Ann Marie BingoManager, Global Patient Advocacy
Horizon Pharma
Anne BrunsAssociate Executive Director and
Operations ManagerThe Atypical HUS Foundation
Moderator:
Panelists:
Its not too late, you can still join us at the
RARE Patient Advocacy Summit and RARE Partnering and Investor Forum
20
21